Fortune August 15, 2022
Chris Morris

Moderna’s “next generation” COVID booster, which targets both the original and Omicron strains of the virus, has been cleared for use in adults in the U.K.

The dose can increase antibody levels to a point where it might only be needed annually, says Moderna’s chief medical officer.

The U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) authorized the booster on Monday.

“We are delighted with the MHRA’s authorization of Spikevax Bivalent Original/Omicron, our next-generation COVID-19 vaccine,” said Stéphane Bancel, CEO of Moderna in a statement. “This bivalent vaccine has an important role to play in protecting people in the U.K. from COVID-19 as we enter the winter months.”

The company says it expects further authorization decisions from other...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article